Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
721-740 of 1,743 trials

Colorectal Cancer Diagnosis: FAPI Imaging Study

We are exploring whether a new imaging method can help diagnose the CSM4 subtype of colorectal cancer more accurately. This study aims to improve detection and treatment options for patients.

Metastatic Colorectal Cancer>2 yearsSafety phase (I)GastroenterologyOncology

Thyroid Eye Disease: Efgartigimod PH20 SC

We are studying a new treatment for adults with thyroid eye disease to see if it reduces eye bulging compared to a placebo. This trial will help us understand its effectiveness and safety.

Thyroid Eye Disease>2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyOphthalmology

Thyroid Eye Disease: Efgartigimod PH20 SC Study

We are testing a new treatment called efgartigimod PH20 SC in adults with thyroid eye disease. The goal is to see if it works better than a placebo in reducing symptoms.

Thyroid Eye Disease>2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyOphthalmology

Cancer Treatment: Immune Therapy with Ultrasound

We are exploring a new treatment combining immune checkpoint inhibition therapy with focused ultrasound for cancer patients. This study aims to determine if this combination enhances the effectiveness of cancer treatment.

Advanced Solid Tumors>2 yearsSafety phase (I)Oncology

Acute Myeloid Leukemia: CD19 CAR-T Cell Therapy

We are studying the safety of a new CAR-T cell treatment for patients with refractory acute myeloid leukemia. This trial aims to see how well the treatment works and how long the CAR-T cells last in the body.

Recurrent Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Non-Small Cell Lung Cancer: New Treatment Combinations with Pembrolizumab

We are studying new investigational treatments combined with pembrolizumab and chemotherapy for patients with newly diagnosed resectable non-small cell lung cancer. The goal is to see how well these combinations work and their safety before surgery.

Non-small Cell Lung Cancer>2 yearsEfficacy phase (II)Investigational MedicinesOncology

MOG Antibody-Associated Disease: Rozanolixizumab Study

We are studying whether Rozanolixizumab is effective and safe for adults with MOG antibody-associated disease. This research aims to provide insights into a potential new treatment for this condition.

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOG-AD)>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurology

Indolent Non-Hodgkin's Lymphoma: EO2463 Cancer Vaccine

We are investigating a new cancer vaccine, EO2463, for patients with indolent Non-Hodgkin's Lymphoma. The trial aims to assess its safety and effectiveness alone and with other treatments.

Indolent Non-Hodgkin's Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Alpha-1 Antitrypsin Deficiency: BEAM-302 Treatment Study

We are exploring a new treatment for adults with Alpha-1 Antitrypsin Deficiency-related lung or liver disease. The study aims to evaluate its safety and effectiveness in improving health outcomes.

Alpha-1 Antitrypsin Deficiency (AATD)>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHepatologyPulmonology

B-cell Non-Hodgkin Lymphoma: JNJ-88998377

We are testing a new treatment for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. This study aims to find a safe dose and understand how the treatment works in humans.

Relapsed or Refractory B-cell Non-Hodgkin Lymphomas>2 yearsSafety phase (I)Oncology

Heart Attack Treatment: EVOLocumab Study

We are studying whether adding evolocumab to standard cholesterol management helps reduce serious heart-related events in patients recently hospitalized for a heart attack. This trial aims to improve outcomes for those affected by acute myocardial infarction.

High Cholesterol>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

ColiFin® Therapy for Adults with Bronchiectasis and Pseudomonas Infection

We are studying whether inhaled ColiFin® can improve health in adults with bronchiectasis who have a new asymptomatic Pseudomonas aeruginosa infection. The trial compares this treatment to standard care to see which is more effective.

Bronchiectasis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology

Advanced Non-Small Cell Lung Cancer: BNT116 Treatment

We are evaluating the safety and early effectiveness of BNT116, both alone and with other treatments, for patients with advanced non-small cell lung cancer. This study aims to find better options for managing this condition.

Advanced Non-Small Cell Lung Cancer>2 yearsSafety phase (I)OncologyPulmonology

TAVI Patients: Ticagrelor vs Aspirin Study

We are comparing the safety and effectiveness of Ticagrelor and Aspirin for patients after Transcatheter Aortic Valve Implantation. This study aims to see which treatment may lead to fewer serious health events and complications.

Aortic Stenosis>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

Late-Onset Pompe Disease: SPK-3006 Infusion Study

We are testing a new intravenous treatment for adults with late-onset Pompe disease to evaluate its safety and potential benefits. This study will help us understand how well the treatment works and how it is tolerated.

Pompe Disease>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyGastroenterologyHematologyNeurology

Advanced Solid Tumors: ABBV-400 Treatment Study

We are evaluating a new treatment for adults with advanced solid tumors to see how safe and effective it is, both alone and with another medication. This study aims to improve options for patients facing these challenging conditions.

Advanced Solid Tumors>2 yearsSafety phase (I)Oncology

C3 Glomerulopathy: Iptacopan Study

We are studying the long-term safety and effectiveness of iptacopan for individuals with C3 glomerulopathy or idiopathic immune-complex-membranoproliferative glomerulonephritis. This research aims to understand how well the treatment works in improving kidney health.

C3 Glomerulopathy>2 yearsConfirmation phase (III)Monitoring phase (IV)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNephrology

Relapsing Multiple Sclerosis: Remibrutinib vs. Teriflunomide

We are studying whether remibrutinib is more effective than teriflunomide in reducing relapses for individuals with relapsing multiple sclerosis. The trial also examines the safety and impact of both treatments on daily life.

Relapsing Multiple Sclerosis>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteNeurology

Multiple Sclerosis: RO7121932 Treatment Study

We are investigating a new treatment for people with multiple sclerosis to see how safe it is and how well it works when given in different ways. This study will help us understand its effects on the immune system and overall health.

Multiple Sclerosis>2 yearsSafety phase (I)Neurology

Systemic Sclerosis-Related Lung Disease: Belimumab Study

We are investigating the long-term safety and effects of belimumab in adults with lung disease linked to systemic sclerosis. This study aims to see how the treatment impacts lung function and overall tolerability.

Lung Involvement in Systemic SclerosisBronchial Diseases>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPulmonologyRheumatology